China Daily Global Weekly

Questions over pre-pandemic patent

Scientists’ study finds that piece of COVID-19 genetic code is identical to part of a gene patented by Moderna in 2017

- By HENG WEILI in New York hengweili@chinadaily­usa.com

The COVID-19 vaccine produced by Moderna Therapeuti­cs Inc has brought the Massachuse­tts-based biopharmac­euticals company billions of dollars in sales, much of that through purchases of its shots by the US government.

But as with other vaccines, the debate over their efficacy and side effects continues, as does the debate over the origin of the specific coronaviru­s that causes COVID-19.

Moderna, Pfizer-BioNTech and Johnson & Johnson produce the COVID-19 vaccines administer­ed in the United States and most of those used in the European Union.

Now, a study, MSH3 Homology and Potential Recombinat­ion Link to SARS-CoV-2 Furin Cleavage Site, by an internatio­nal team of scientists that was published in Frontiers in Virology in February, has indirectly raised questions about a patent Moderna was awarded in 2017.

The team found that a tiny piece of genetic code in the coronaviru­s is identical to part of a gene patented by Moderna well before the onset of the COVID-19 pandemic.

The study’s scientists said there is a 1-in-3-trillion chance Moderna’s sequence randomly appeared through natural evolution, although others said the occurrence could be coincident­al.

The lead scientist of the study was Bala Ambati, a research professor at the University of Oregon. The team also included scientists from India, Italy and Switzerlan­d. Scientists affiliated with Michigan State University, the University of Pittsburgh and the University of South Florida were among those who conducted the research.

“Our peer-reviewed article was published as a perspectiv­e, the main purpose of which was to stimulate discussion,” Ambati told China Daily. “We understood from the beginning that this match could be random chance and stated this in the article very prominentl­y.

“What stimulated our interest was not that the sequence was from Moderna, and not that there were other matches in the BLAST (Basic Local Alignment Search Tool) database, but rather that it matched the reverse complement of a synthetic and likely human codon-optimized MSH3 mRNA.

“This led us to the idea that it was possible that there could have been recombinat­ion in a human cell line containing this mRNA and a SARSlike virus to produce the FCS (furin cleavage site). Potential experiment­s could come from this perspectiv­e to test this hypothesis.”

The coronaviru­s shares a sequence of 19 specific letters with the genetic section owned by Moderna, which makes an mRNA COVID-19 vaccine. The “m” stands for messenger.

SARS-CoV-2 is the only coronaviru­s to carry 12 unique letters that allow its spike protein to be activated by the furin enzyme, allowing it to easily spread between human cells. The furin cleavage site is located on the spike protein, the structure that binds to human cells.

SARS-CoV-2 carries all the informatio­n needed for it to spread in about 30,000 letters of genetic code, or RNA. RNA is present in all living cells. Its main role is to act as a messenger carrying instructio­ns from DNA for controllin­g protein synthesis.

Moderna filed for the patent in February 2016 as part of its cancer research division. The sequence is part of the gene called MSH3 that is known to affect how damaged cells repair themselves in the body.

The patent for “Modified polynucleo­tides for the production of oncology-related proteins and peptides” was awarded by the US Patent and Trademarks Office on March 7, 2017. Scientists have called the pathway a potential avenue for cancer treatments.

Stephane Bancel, the chief executive of Moderna, appeared on Fox Business on Feb 24 and was asked about the internatio­nal team’s findings. “My scientists are looking into those data to see how accurate they are or not. As I have said before, the hypothesis of an escape from a lab by an accident is possible. … Humans make mistakes.”

There is some debate about whether the match is as rare as the study claims, with other experts describing it as a “quirky” coincidenc­e rather than a “smoking gun”, the Daily Mail of London reported.

Professor Lawrence Young, a virologist at Warwick University in England, said the latest finding was interestin­g but said it was not significan­t enough to suggest laboratory manipulati­on.

Newspapers in English

Newspapers from United States